Drop out > lost to follow up.
Drop out = lost to follow up + early discontinuation
lost to follow up ≠ early discontinuation
Добровольно прекратившие прием дабигатрана были тяжелее.
Цитата:
|
I want to highlight is, if you had a stroke you tended to discontinue more so in the dabigatran arm. If you had a TIA, again, true. And if you had a minor bleed, again we see the same pattern. What does this mean? What do we make of it? I think, sort of, there’s two key messages to take home from this. One has to do with the way that we do analyses on RE-LY, though there were some questions raised by the committee about looking at on-treatment or as-treated analyses. I think that this fact or this observation that patients who were sicker tended to discontinue from study drug preferentially in the dabigatran arm raises some concerns about looking at as-treated or on-treatmen analyses.
|
The FDA transcript
Кроме того, мне кажется, неравномерное выбывание из-за ЖКТ проблем приводит к недооценки риска GI кровотечений на дабигатране в исследовании.